References
- Future-proofing Western Europe's Healthcare. A study of five countries. A report from the Economist Intelligence Unit. The Economist, September 2011. 2011. Available from: http://www.economistinsights.com/sites/default/files/downloads/EIU-Eucomed-Future-proofing healthcare_Final_Web.pdf [cited 20 March 2016].
- European Economy. Joint report on health systems. European Commission and the Economic Policy Committee. Occasional papers 74, December 2010. 2010. Available from: http://ec.europa.eu/economy_finance/publications/occasional_paper/2010/pdf/ocp74_en.pdf [cited 20 March 2016].
- Progressions: Navigating the payer landscape. Global Pharmaceutical Report, 2014. Available from: http://www.ey.com/GL/en/Industries/Life-Sciences/EY-progression-2014 [cited 20 March 2016].
- Gragnolati M, Lindelow M, Couttolenc B. Twenty years of health system reform in Brazil: An assessment of the sistema unico de saude. 2013; DC: World Bank: Washington. Available from: http://documents.worldbank.org/curated/en/2013/01/17899895/twenty-years-health-system-reform-brazil-assessment-sistema-unico-de-saude [cited 20 March 2016].
- Daemmrich A, Mohanty A. Healthcare reform in the United States and China: Pharmaceutical market implications. J Pharm Policy Pract. 2014; 7(1): 9. [PubMed Abstract] [PubMed CentralFull Text].
- Boynton XL, Ma O, Schmalzback MC. Reforming health care in China: Payment system reform and health technology assessment. Center for Strategic International Studies, December 2012. Available from: http://csis.org/files/publication/121207_Boynton_KeyIssuesChinaHealth_Web.pdf [cited 20 March 2016].
- Kanavos P, Nicod E, van den Aardweg S, Pomedli S. The impact of health technology assessments: An international comparison. Euro Observer. 2010; 12(4): 1–17.
- Houÿez F, Tessier L, Synodinos D. Health care cost-containment measures in the context of the economic crisis: Impact analysis. Orphanet J Rare Dis. 2014; 9(Suppl 1): O21.
- Backhouse ME, Wonder M, Hornby E, Kilburg A, Drummond M, Mayer FK. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: A pilot study. Value Health. 2011; 14(4): 608–15. [PubMed Abstract].
- European Medicines Agency (EMA). Best practice guidance for pilot EMA HTA parallel scientific advice procedures. A Report. EMA/109608/2014. May 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/05/WC500166226.pdf [cited 20 March 2016]..
- Moseley J, Warner J, Sibal A. Parallel EMA-HTA advice: Past, present, and future. Regulatory Rapporteur. 2015; 12(1): 7–9.
- Neumann PJ, Cohen JT. Measuring the value of prescription drugs. N Engl J Med. 2015; 373: 2595–7. [PubMed Abstract].
- Zweigenhaft B, Bosserman L, Kenney JTJr, Lawless GD, Marsland TA, Deligdish CK, etal. Defining value in cancer care: AVBCC 2013 steering committee report. Am Health Drug Benefits. 2013; 6(5): 236–46. [PubMed Abstract] [PubMed CentralFull Text].
- Sharp C. Show me the evidence. How European payers are re-prioritising for the future. 2013; London, UK: Eyeforpharma FC Business Intelligence Ltd.
- Porter ME. What is value in health care?. N Engl J Med. 2010; 363: 2477–81. [PubMed Abstract].
- Simeons S. How to assess the value of medicines?. Front Pharmacol. 2010; 1: 115.
- Rémuzat C, Toumi M, Falissard B. New drug regulations in 260 France: What are the impacts on market access? Part 1 – Overview of new drug regulations in France. 2013; J Mark Access Health Policy. 1: 20891. doi: http://dx.doi.org/10.3402/jmahp.v1i0.20891.
- Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, etal. Updating the American Society of Clinical Oncology Value Framework: Revisions and reflections in response to comments received. J Clin Oncol. 2016. pii: JCO682518.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™. Available from: https://www.nccn.org/evidenceblocks [cited 20 March 2016]..